Analyst Price Targets — TTOO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 30, 2024 6:27 am | Kyle Mikson | Canaccord Genuity | $5.00 | $4.74 | StreetInsider | T2 Biosystems, Inc (TTOO) PT Raised to $5 at Canaccord Genuity |
Latest News for TTOO
T2 Biosystems (NASDAQ: TTOO - Get Free Report) and Biostage (OTCMKTS:BSTG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings. Earnings and Valuation This table compares T2 Biosystems
Risk and Volatility Acutus Medical has a beta of -1.28, meaning that its stock price is 228% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Profitability This table compares Acutus Medical and T2 Biosystems' net margins,
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TTOO.
U.S. House Trading
No House trades found for TTOO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.